- Cancer Takes Tough Toll on Family Finances
- You Might Fare Better If Your Doctor Is Female, Study Finds
- CDC Launches Online ‘Heat Forecaster’ Tool as Another Summer Looms
- Biden Administration Sets Nursing Home Staffing Minimums
- Neosporin Ointment in the Nose Might Be Potent Antibiotic
- Physical Ills Often Plague People With Schizophrenia, Bipolar
- Taking Psilocybin for Depression? Relationship With Therapist Is Key
- Stick to Heimlich Maneuver Not ‘Anti-Choking’ Devices, FDA Says
- Women in the Military at Risk for Low-Weight Babies
- Repeat Blasts Can Damage Soldiers’ Brains, Study Confirms
Cresemba Approved for Serious Fungal Infections
Cresemba (isavuconazonium sulfate) has been approved by the U.S. Food and Drug Administration to treat rare but serious fungal infections, mostly affecting people with weakened immune systems, the agency said Friday in a news release.
The infections are caused by Aspergillus and Mucorales fungi. The new drug, targeting the cell walls of the fungi, is available in oral and intravenous formulations.
Cresmba’s safety and effectiveness were evaluated in clinical studies involving more than 500 people. The most common side effects included nausea, vomiting, diarrhea, headache, low blood potassium, constipation, shortness of breath, coughing and tissue swelling. More serious adverse effects could include liver problems and allergic reactions.
Cresemba is marketed by Astellas Pharma US, based in Northbrook, Ill.
More information
The FDA has more about this approval.
Source: HealthDay
Copyright © 2024 HealthDay. All rights reserved.